|Articles|September 15, 2002
- BioPharm International-09-01-2002
- Volume 15
- Issue 9
Security in the Corporate Homeland
Author(s)Joseph F. Noferi, Esq.
by Joseph F. Noferi, Chimeric Therapies, Inc.
Advertisement
Articles in this issue
about 23 years ago
Reexamining the Set It and Forget It Approachabout 23 years ago
Integrating New Technology into Blood Plasma Fractionationabout 23 years ago
Attack Mounts on Pharmaceutical Pricesabout 23 years ago
If a Tree Fell in the ForestNewsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
Advertisement
Advertisement
Advertisement
Trending on BioPharm International
1
Neurimmune and AstraZeneca Expand Efforts to Accelerate Fibril-Depleting Therapies
2
Roche Drives Industry Shift With Three-Year Lymphoma Survival Data
3
How Mitigation and Maintenance Protect Against Future Risk
4
New Lymphoma Indication for CAR T-Cell Therapy Shapes Pipeline
5
